ArticleThe Journal of clinical investigation2025

Integrated screening identifies GPR31 as a key driver and druggable target for metabolic dysfunction-associated steatohepatitis.

Xiao-Jing Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.